RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA
Clinical trials for RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New CAR-T therapy aims to control Hard-to-Treat blood cancers
Disease control Recruiting nowThis study tests a new treatment called Talikabtagene autoleucel (NexCAR19) for adults with certain blood cancers that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells, which are modified in a lab to better recognize and attack …
Matched conditions: RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA
Phase: PHASE2, PHASE3 • Sponsor: Health Institutes of Turkey • Aim: Disease control
Last updated May 26, 2026 07:00 UTC
-
New hope for hard-to-treat lymphoma: experimental drug targets cancer from within
Disease control Recruiting nowThis study tests a new drug, BMS-986458, in about 308 adults with non-Hodgkin lymphoma that returned or didn't respond to prior treatments. The drug works by breaking down a protein that helps cancer cells grow. Researchers will check safety, side effects, and whether the drug sh…
Matched conditions: RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated May 26, 2026 06:59 UTC